Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review

被引：0
|
作者：
Francesco Spagnolo
Andrea Boutros
Federica Cecchi
Elena Croce
Enrica Teresa Tanda
Paola Queirolo
机构：
[1] IRCCS Ospedale Policlinico San Martino,Medical Oncology 2
[2] European Institute of Oncology (IEO),Melanoma, Sarcoma & Rare Tumors Division
来源：
BMC Cancer | / 21卷
关键词：
Melanoma; Immunotherapy; Immune-related response criteria; Treatment beyond progression; Anti-PD-1;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment
    Sanchez-Magraner, Lissete
    Miles, James
    Baker, Claire L.
    Applebee, Christopher J.
    Lee, Dae-Jin
    Elsheikh, Somaia
    Lashin, Shaimaa
    Withers, Katriona
    Watts, Andrew G.
    Parry, Richard
    Edmead, Christine
    Lopez, Jose Ignacio
    Mehta, Raj
    Italiano, Antoine
    Ward, Stephen G.
    Parker, Peter J.
    Larijani, Banafshe
    CANCER RESEARCH, 2020, 80 (19) : 4244 - 4257
  • [32] The predictive value of PD-L1 expression in response to anti-PD-1/PD-L1 therapy for biliary tract cancer: a systematic review and meta-analysis
    Yoon, Seung Bae
    Woo, Sang Myung
    Chun, Jung Won
    Kim, Dong Uk
    Kim, Jaihwan
    Park, Joo Kyung
    So, Hoonsub
    Chung, Moon Jae
    Cho, In Rae
    Heo, Jun
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [33] Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis
    Wang, Xiaohui
    Bao, Zhengqiang
    Zhang, Xiaoju
    Li, Fei
    Lai, Tianwen
    Cao, Chao
    Chen, Zhihua
    Li, Wen
    Shen, Huahao
    Ying, Songmin
    ONCOTARGET, 2017, 8 (35) : 59901 - 59914
  • [34] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
    Niu, Mengke
    Yi, Ming
    Li, Ning
    Luo, Suxia
    Wu, Kongming
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2021, 10 (01)
  • [35] Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
    Mengke Niu
    Ming Yi
    Ning Li
    Suxia Luo
    Kongming Wu
    Experimental Hematology & Oncology, 10
  • [36] Microbiota and Extracellular Vesicles in Anti-PD-1/PD-L1 Therapy
    Mishra, Surbhi
    Amatya, Sajeen Bahadur
    Salmi, Sonja
    Koivukangas, Vesa
    Karihtala, Peeter
    Reunanen, Justus
    CANCERS, 2022, 14 (20)
  • [37] The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review
    Chen, Ke
    Wang, Xiao
    Yang, Liu
    Chen, Zheling
    CANCER CONTROL, 2021, 28
  • [38] PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas
    Perottet, Jeremy
    Le Goff, Emeline
    Legoupil, Delphine
    Quere, Gilles
    Schick, Ulrike
    Marcorelles, Pascale
    Uguen, Arnaud
    APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2020, 28 (02) : 161 - 165
  • [39] Clinical observation of the efficacy of PD-1/PD-L1 inhibitors in the treatment of patients with advanced solid tumors
    Wang, Miao
    Zhen, Hongchao
    Jiang, Xiaoyue
    Lu, Yuting
    Wei, Yuhan
    Jin, Jiangtao
    Li, Qin
    IMMUNITY INFLAMMATION AND DISEASE, 2021, 9 (04) : 1584 - 1595
  • [40] The efficacy and safety of anti-PD-1/PD-L1 antibodies for treatment of advanced or refractory cancers: a meta-analysis
    Zhang, Tengfei
    Xie, Jing
    Arai, Seiji
    Wang, Liping
    Shi, Xuezhong
    Shi, Ni
    Ma, Fen
    Chen, Sen
    Huang, Lan
    Yang, Li
    Ma, Wang
    Zhang, Bin
    Han, Weidong
    Xia, Jianchuan
    Chen, Hu
    Zhang, Yi
    ONCOTARGET, 2016, 7 (45) : 73068 - 73079
12345